Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer.
Franken MD, van Rooijen EM, May AM, Koffijberg H, van Tinteren H, Mol L, Ten Tije AJ, Creemers GJ, van der Velden AMT, Tanis BC, Uyl-de Groot CA, Punt CJA, Koopman M, van Oijen MGH.
Franken MD, et al. Among authors: koopman m.
Eur J Cancer. 2017 Apr;75:204-212. doi: 10.1016/j.ejca.2017.01.019. Epub 2017 Feb 24.
Eur J Cancer. 2017.
PMID: 28237866
Clinical Trial.